#United States #New Haven #Trevi Therapeutics #Haduvio #IPF

Trevi Therapeutics Financial Results and Business Updates

On August 7, 2025, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical firm based in Connecticut, shared its second-quarter financial results alongside updates on its investigational therapy, Haduvio™. Haduvio is designed to treat chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) among other conditions.

Significant Trial Results

Trevi recently announced positive topline results from its Phase 2b CORAL trial. This trial specifically evaluated Haduvio for chronic cough among IPF patients, involving 165 individuals. The results were quite promising, with Haduvio achieving the primary endpoint characterized by statistically significant reductions in 24-hour cough frequency across all dosage groups. The reductions observed were exceptional: a 60.2% decrease in the 108 mg bid group, 53.4% in the 54 mg bid group, and 47.9% in the 27 mg bid group, as compared to just a 16.9% reduction in the placebo group (p<0.0001).

Jennifer Good, President and CEO of Trevi Therapeutics, highlighted these results as a significant milestone. She emphasized the importance of addressing the debilitating nature of chronic cough in patients with IPF and noted that the company is gearing up to hold an End-of-Phase 2 meeting with the FDA later this year, aiming to align on their Phase 3 program set to begin in early 2026.

Financial Health of Trevi Therapeutics

In terms of financials, Trevi concluded the second quarter of 2025 with $203.9 million in cash, cash equivalents, and marketable securities, bolstering a projected cash runway extending into 2029. This position enables the firm to continue advancing Haduvio through late-stage development as well as engage in pre-commercial planning activities. During the quarter, Trevi successfully completed a $115 million underwritten offering, further enhancing its financial stability.

Key Financial Metrics

Research and development (R&D) expenses saw a decrease, falling to $9.4 million from $10.0 million in the same period of the previous year. Lower clinical development expenses, especially related to ongoing trials in 2024, contributed to this decline. Conversely, general and administrative (G&A) expenses rose to $4.3 million—up from $3.3 million year-on-year—primarily due to increased professional fees and personnel costs.

Looking at net loss figures, Trevi reported a $12.3 million loss for the quarter, which slightly improved from a loss of $12.4 million in the equivalent quarter of 2024. Interestingly, net other income rose to $1.4 million during this timeframe, marking an increase attributed to higher investment income on its cash and marketable securities.

Company Strategy and Next Steps

As Trevi Therapeutics continues its innovative trajectory, upcoming events and conferences will feature the company's leadership. Notable conferences include Stifel's Biotech Summer Summit and the European Respiratory Society Congress, both serving as venues for sharing insights into Haduvio's development.

The Need for a Breakthrough

Chronic cough is a debilitating condition that affects a significant percentage of individuals with IPF, and current treatment options are limited. Haduvio has the potential to transform the management of chronic cough, not only improving patients' health outcomes but also enhancing their quality of life—vital for a demographic facing serious respiratory challenges.

As Trevi Therapeutics forges ahead with Haduvio, stakeholders and patients alike are hopeful that this innovative therapy will yield the satisfactory results projected and fill a notable gap in current medical offerings. For updates and more information about Trevi Therapeutics, visit the official website and follow their social media channels.